Effect of periodontal treatments on serum IgG antibody titers against periodontopathic bacteria.
Serum IgG antibody titers to 7 periodontopathic bacteria in periodontitis patients were measured at the 1st visit and after various periodontal treatments with clinically successful improvement, in order to evaluate what kind of factors are associated with changes of serum antibody titers. 20 patients (10 male and 10 female from 23 to 61 years old) with adult, rapidly progressive periodontitis were enrolled in this study. All patients received initial preparation and most of them also underwent surgical procedure. After the treatments, the mean probing pocket depths decreased from 3.72 mm to 1.56 mm. Serum samples were collected from patients at the initial and final examinations. Serum IgG antibody titers against sonicated antigens of Porphyromonas gingivalis FDC 381, Prevotella intermedia ATCC 25611, Prevotella loescheii ATCC 15930, Fusobacterium nucleatum subspecies nucleatum ATCC 25586, Actinobacillus actinomycetemcomitans FDC Y4, Eikenella corrodens FDC 1073 and Capnocytophaga ochracea # M 12 were determined by enzyme-linked immunosorbent assay. The mean antibody titers to P. gingivalis and P. intermedia decreased significantly after the treatment as compared to their pretreatment levels. The antibody titer to P. gingivalis, especially, decreased in all of the patients examined. A significant relationship was found between the decreased antibody titer to P. gingivalis and the number of teeth which received periodontal surgery, as well as treatment length, and the relationship between the decreased antibody titer to P. intermedia and the number of extracted teeth was also significant. These results suggest that the changes of serum IgG titers against P. gingivalis and P. intermedia are related to the suppression of such pathogens in subgingival plague.
Horibe
M
M
Department of Periodontology, Faculty of Dentistry, Tokyo Medical and Dental University, Japan.
Watanabe
H
H
Ishikawa
I
I
D000328:Adult; D016976:Aggregatibacter actinomycetemcomitans / Q000276:immunology; D016301:Alveolar Bone Loss / Q000382:microbiology / Q000601:surgery / Q000628:therapy; D000907:Antibodies, Bacterial / Q000097:blood*; D001419:Bacteria / Q000276:immunology*; D002206:Capnocytophaga / Q000276:immunology; D012534:Dental Scaling; D016124:Eikenella corrodens / Q000276:immunology; D005260:Female; D016967:Fusobacterium nucleatum / Q000276:immunology; D006801:Humans; D007074:Immunoglobulin G / Q000097:blood*; D008297:Male; D008875:Middle Aged; D010514:Periodontal Pocket / Q000382:microbiology / Q000601:surgery / Q000628:therapy; D010518:Periodontitis / Q000382:microbiology* / Q000601:surgery / Q000628:therapy*; D016966:Porphyromonas gingivalis / Q000276:immunology; D018720:Prevotella / Q000276:immunology; D018713:Prevotella intermedia / Q000276:immunology; D016745:Root Planing
D000907:Antibodies, Bacterial; D007074:Immunoglobulin G